Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Valneva (NASDAQ:VALN – Free Report) had its target price trimmed by HC Wainwright from $18.00 to $17.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage ...

H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Ratings for Valneva (NASDAQ:VALN) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

In a report released on February 18, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...

Valneva expects further sales growth this year after it posted higher revenue in 2024.

VALNEVA Declaration of shares and voting rights January 31, 2025_____ Company name: VALNEVARegistered office ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...